Publikationen
Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer
Klümper N, Cox A, Sjödahl G, Roghmann F, Bolenz C, Hartmann A, Grünwald V, Faltas BM, Hölzel M, Eckstein M. Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer. Nat Rev Urol. 2024 Oct 29. doi: 10.1038/s41585-024-00951-2. Epub ahead of print. PMID: 39472646.
Molecular heterogeneity of druggable targets between localized muscle-invasive and metastatic urothelial cancer. Molecular changes during metastatic spread of urothelial carcinoma can lead to a sampling bias with potential effect on selection for targeted therapies. ADC, antibody–drug conjugate; CNA, copy number alteration; FGFR, fibroblastic growth factor receptor; MET, metastasis.
Branz A, Matek C, Lange F, Bahlinger V, Klümper N, Hölzel M, Strissel PL, Strick R, Sikic D, Wach S, Taubert H, Wullich B, Hartmann A, Seliger B, Eckstein M. HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance. Front Immunol. 2024 Oct 14;15:1478196. doi: 10.3389/fimmu.2024.1478196. PMID: 39469714; PMCID: PMC11513269.
Membranous expression of target protein is required for ADC response in urothelial cancer
Klümper N, Brägelmann J, Bahlinger V, Hartmann A, Grünwald V, Kuppe C, Hölzel M, Eckstein M. Membranous expression of target protein is required for ADC response in urothelial cancer. Eur Urol. 2024 Jul 31:S0302-2838(24)02491-6. doi: 10.1016/j.eururo.2024.06.023. Epub ahead of print. PMID: 39089924.
Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. J Clin Oncol. 2024 Jul 10;42(20):2446-2455. doi: 10.1200/JCO.23.01983. Epub 2024 Apr 24. PMID: 38657187; PMCID: PMC11227306.
PFS (A) and OS (B) upon initiation of EV treatment stratified by presence of NECTIN4gene amplification versus high membranous NECTIN4 protein expression without NECTIN4gene amplification. EV, enfortumab vedotin; OS, overall survival; PFS, progression-free survival.
Klümper N, Eckstein M. Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer. Eur Urol Focus. 2024 Mar;10(2):224-226. doi: 10.1016/j.euf.2024.04.001. Epub 2024 Apr 16. PMID: 38631991.
An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer
Reike MJ, Reicherz A, Tully KH, Bahlburg H, Maas M, Bach P, Klümper N, Eckstein M, Hartmann A, Breyer J, Erben P, Bolenz C, Noldus J, Berg S, Roghmann F. An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer. Urol Int. 2024;108(3):183-189. doi: 10.1159/000536321. Epub 2024 Jan 19. PMID: 38246156.
Bahlinger V, Branz A, Strissel PL, Strick R, Lange F, Geppert CI, Klümper N, Hölzel M, Wach S, Taubert H, Sikic D, Wullich B, Angeloni M, Ferrazzi F, Diehl L, Kovalenko M, Elboudwarej E, Jürgensmeier JM, Hartmann A, Eckstein M. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts. Histopathology. 2024 Apr;84(5):863-876. doi: 10.1111/his.15130. Epub 2024 Jan 9. PMID: 38196202.
Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma
Hosni S, Kilian V, Klümper N, Gabbia D, Sieckmann K, Corvino D, Winkler A, Saponaro M, Wörsdörfer K, Schmidt D, Hahn O, Zanotto I, Bertlich M, Toma M, Bald T, Eckstein M, Hölzel M, Geyer M, Ritter M, Wachten D, De Martin S, Alajati A. Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma. Cancer Res. 2024 Mar 4;84(5):725-740. doi: 10.1158/0008-5472.CAN-23-1398. PMID: 38175774; PMCID: PMC10911805.
Saal J, Grünwald V, Bald T, Ritter M, Brossart P, Tomita Y, Hartmann A, Hölzel M, Eckstein M, Klümper N. On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy. Eur Urol Oncol. 2024 Jun;7(3):328-331. doi: 10.1016/j.euo.2023.11.005. Epub 2023 Nov 22. PMID: 37996277.
Prognostic information from the on-treatment modified Glasgow Prognostic Score (mGPS) for patients with metastatic urothelial carcinoma treated with immunotherapy in the phase 2 IMvigor210 and phase 3 IMvigor211 trials. Overall survival probability for the subsets of patients with stable disease or progressive disease at first staging in the IMvigor210 and IMvigor211 trials.
Klümper N, Wüst L, Saal J, Ralser DJ, Zarbl R, Jarczyk J, Breyer J, Sikic D, Wullich B, Bolenz C, Roghmann F, Hölzel M, Ritter M, Strieth S, Hartmann A, Erben P, Wirtz RM, Landsberg J, Dietrich D, Eckstein M. PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. Oncoimmunology. 2023 Oct 19;12(1):2267744. doi: 10.1080/2162402X.2023.2267744. PMID: 37868689; PMCID: PMC10588513.
(a) Distribution of mPD-L1 stratified by response at first staging according to RECIST (CR=complete response, PR=partial response, SD=stable disease, PD=progressive disease; Mann–Whitney U tests: PD vs. SD P = 0.49, PD vs. PR P = 0.13, PD vs. CR P = 0.003, SD vs. PR P = 0.56, SD vs. CR P = 0.12, PR vs. CR P = 0.20). Kaplan–Meier survival curves showing the progression-free (PFS, b) and overall survival (OS, c) after ICB initiation stratified according to mPD-L1 status (quartiles).
Zschäbitz S, Biernath N, Hilser T, Höllein A, Zengerling F, Cascucelli J, Paffenholz P, Seidl D, Lutz C, Schlack K, Kingreen D, Klümper N, Ivanyi P, von Amsberg G, Heers H, Roghmann F, Tauber RL, Cathomas R, Hofer L, Niegisch G, Klee M, Ehrenberg R, Hassler A, Hadaschik BA, Grünwald V, Darr C. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort. Eur Urol Open Sci. 2023 May 17;53:31-37. doi: 10.1016/j.euros.2023.04.018. PMID: 37441344; PMCID: PMC10334227.
Klümper N, Ellinger J. Insights into Urologic Cancer. Cancers (Basel). 2023 Jun 8;15(12):3108. doi: 10.3390/cancers15123108. PMID: 37370718; PMCID: PMC10295856.
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution
Cox A, Klümper N, Stein J, Sikic D, Breyer J, Bolenz C, Roghmann F, Erben P, Wirtz RM, Wullich B, Ritter M, Hölzel M, Schwamborn K, Horn T, Gschwend J, Hartmann A, Weichert W, Erlmeier F, Eckstein M. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. 2024 Apr;85(4):328-332. doi: 10.1016/j.eururo.2023.03.020. Epub 2023 Apr 6. PMID: 37031005.
(C) PRIM to distant MET evolution of molecular tumor subtypes in 138 matched PRIM and MET. In total, 183 samples were classified as luminal (PRIM: n = 91; MET: n = 92), 81 as basal (PRIM: n = 41; MET: n = 40), and 12 DN (neuroendocrine carcinomas; PRIM: n = 6; MET: n = 6). Overall concordance rate across all subtypes amounted to 94% (95% CI 88–97%). Stability of DN tumors amounted to 100% (95% CI 54–100%). Five basal and four luminal PRIM tumors switched their subtype to luminal or basal, respectively. (D) PRIM to distant MET evolution of histomorphological appearance in 138 matched PRIM and MET; 178 tumors presented with NOS morphology (conventional urothelial morphology; PRIM: n = 92; MET: n = 86), 42 with divergent squamous differentiation (PRIM: n = 21; MET: n = 21), 44 with subtype histology (prior so-called “variant” histology; PRIM: n = 19; MET: n = 25), and 12 with small-cell neuroendocrine morphology (small-cell neuroendocrine carcinomas; PRIM: n = 6; MET: n = 6). The overall concordance rate of histomorphological appearance between PRIM and MET amounted to 94% (95% CI 89–98%).
Saponaro M, Flottmann S, Eckstein M, Hommerding O, Klümper N, Corvino D, Hosni S, Schmidt A, Mönig N, Schmidt D, Ellinger J, Toma M, Kristiansen G, Bald T, Alimonti A, Ritter M, Hölzel M, Alajati A. CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression. Sci Rep. 2023 Jan 2;13(1):73. doi: 10.1038/s41598-022-26579-z. Erratum in: Sci Rep. 2023 Feb 17;13(1):2838. doi: 10.1038/s41598-023-28942-0. PMID: 36593286; PMCID: PMC9807563.
(H) CDCP1 TPM across the UC subtypes showing the high expression of CDCP1 in the Ba/Sq subtype. Tumor samples are correspondent to the ones from the MIBC TMA. (I) Kaplan–Meier survival analysis of UC patients treated with chemotherapy stratified based on the semi-quantitative expression of CDCP1 (CDCP1-low: negative, weak; CDCP1-high: moderate, strong). *P < 0.05. Statistical test: Gehan–Breslow–Wilcoxon test.
Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M, Eckstein M. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764. PMID: 36534531; PMCID: PMC10102834.
Membranous NECTIN-4 protein expression patterns assessed by IHC. A and B, Membranous NECTIN-4 expression decreases significantly during metastatic spread of urothelial carcinoma, with 39.4% of MET lacking NECTIN-4 expression. P values were calculated by a nonparametric Mann–Whitney test. C–E, Representative IHC stainings for NECTIN-4. Each panel resembles pairs of matched PRIM and distant MET. C, Concordantly negative PRIM and MET (membranous H-score 0).
Erlmeier F, Klümper N, Landgraf L, Strissel PL, Strick R, Sikic D, Taubert H, Wach S, Geppert CI, Bahlinger V, Breyer J, Ritter M, Bolenz C, Roghmann F, Erben P, Schwamborn K, Wirtz RM, Horn T, Wullich B, Hölzel M, Hartmann A, Gschwend JE, Weichert W, Eckstein M. Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. Eur Urol. 2023 Feb;83(2):133-142. doi: 10.1016/j.eururo.2022.10.020. Epub 2022 Nov 10. PMID: 36372626.
Klümper N, Sikic D, Saal J, Büttner T, Goldschmidt F, Jarczyk J, Becker P, Zeuschner P, Weinke M, Kalogirou C, Breyer J, Burger M, Nuhn P, Tully K, Roghmann F, Bolenz C, Zengerling F, Wirtz RM, Muders M, Kristiansen G, Bald T, Ellinger J, Wullich B, Hölzel M, Hartmann A, Erben P, Ritter M, Eckstein M. Eur J Cancer. 2022 May;167:13-22. doi: 10.1016/j.ejca.2022.02.022. Epub 2022 Mar 30. PMID: 35366569
(A) Distribution of baseline CRP across different CRP kinetics groups. (B) Distribution of PD-L1 expression across CRP kinetics groups assessed as combined positivity score (CPS). The dashed line indicates CPS of 10% as a threshold for first-line pembrolizumab therapy in cisplatin-ineligible mUC. (C) Distribution of best RECIST-based response across CRP kinetics groups (PR = partial remission, CR = complete remission, SD = stable disease, PD = progressive disease). Progression-free survival (PFS; D) and overall survival (OS; E) after ICB initiation stratified according to CRP kinetics groups. Median PFS/OS per subgroup is indicated as dotted line.
Mayr R, Eckstein M, Wirtz RM, Santiago-Walker A, Baig M, Sundaram R, Carcione JC, Stoehr R, Hartmann A, Bolenz C, Burger M, Otto W, Erben P, Breyer J. Eur Urol. 2022 Mar 26:S0302-2838(22)01670-0. doi: 10.1016/j.eururo.2022.02.028. Online ahead of print. PMID: 35351346
Sikic D, Eckstein M, Weyerer V, Kubon J, Breyer J, Roghmann F, Kunath F, Keck B, Erben P, Hartmann A, Wirtz RM, Wullich B, Taubert H, Wach S. Urol Oncol. 2022 Feb;40(2):63.e9-63.e18. doi: 10.1016/j.urolonc.2021.06.021. Epub 2021 Jul 28. PMID: 34330652
Sikic D, Weyerer V, Geppert CI, Bertz S, Lange F, Taubert H, Wach S, Schmitz-Draeger BJ, Wullich B, Hartmann A, Eckstein M.
Urol Oncol. 2021 Aug 20:S1078-1439(21)00343-4. doi: 10.1016/j.urolonc.2021.07.025.
The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
Sikic D, Taubert H, Breyer J, Eckstein M, Weyerer V, Keck B, Kubon J, Otto W, Worst TS, Kriegmair MC, Erben P, Hartmann A, Wullich B, Wirtz RM, Wach S. Cancer Manag Res. 2021 Aug 20;13:6567-6578. doi: 10.2147/CMAR.S318893. eCollection 2021. PMID: 34447272 Free PMC article.
Eckstein M, Lieb V, Jung R, Sikic D, Weigelt K, Stöhr R, Geppert C, Weyerer V, Bertz S, Serrero G, Yue B, Hartmann A, Wullich B, Taubert H, Wach S.
Cells. 2021 Jul 15;10(7):1796. doi: 10.3390/cells10071796. PMID: 34359965 Free PMC article.
GP88 immunohistochemical staining in TCs and ICs. Upper row, (A) TCs, positive (ICs, negative); (B) positive ICs with >0% GP88 positivity (TCs, negative); lower row, (C) TCs and ICs, negative. All photomicrographs are at 20× objective magnification.
Sikic D, Taubert H, Wirtz RM, Breyer J, Eckstein M, Weyerer V, Kubon J, Erben P, Bolenz C, Burger M, Hartmann A, Wullich B, Wach S, Keck B. Life (Basel). 2021 Jun 30;11(7):642. doi: 10.3390/life11070642. PMID: 34209360
Weyerer V, Strissel PL, Strick R, Sikic D, Geppert CI, Bertz S, Lange F, Taubert H, Wach S, Breyer J, Bolenz C, Erben P, Schmitz-Draeger BJ, Wullich B, Hartmann A, Eckstein M. Cancers (Basel). 2021 May 12;13(10):2327. doi: 10.3390/cancers13102327. PMID: 34066058 Free PMC article.
Jütte H, Reike M, Wirtz RM, Kriegmair M, Erben P, Tully K, Weyerer V, Eckstein M, Hartmann A, Eidt S, Wezel F, Bolenz C, Tannapfel A, Noldus J, Roghmann F. J Pers Med. 2021 May 26;11(6):473. doi: 10.3390/jpm11060473. PMID: 34073233
Neuropilin-2 and Its Transcript Variants Correlate with Clinical Outcome in Bladder Cancer.
Förster S, Givehchi M, Nitschke K, Mayr T, Kilian K, Dutta S, Datta K, Nuhn P, Popovic Z, Muders MH, Erben P.
Genes (Basel). 2021 Apr 9;12(4):550. doi: 10.3390/genes12040550. PMID: 33918816 Free PMC article.
Quality assessment of radical cystectomy-opportunities, risks, challenges.
Roghmann F, Breyer J, Kriegmair M, Wezel F, Burger M, Noldus J, Bolenz C; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium e. V.. Urologe A. 2021 Feb;60(2):151-161. doi: 10.1007/s00120-020-01439-8. Epub 2021 Jan 22. PMID: 33481063 Review. German.
Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, Wullweber A, Lange F, Erben P, Stoehr R, Bertz S, Geppert CI, Fuhrich N, Taubert H, Wach S, Breyer J, Otto W, Burger M, Bolenz C, Keck B, Wullich B, Hartmann A, Sikic D; BRIDGE Consortium e.V., Mannheim, Germany.
J Immunother Cancer. 2020 May;8(1):e000162. doi: 10.1136/jitc-2019-000162. PMID: 32448798 Free PMC article.
Adjuvant chemotherapy cohort (TCGA +CCC EMN): (A) unsupervised hierarchical cluster analysis (Average-linkage algorithm) of CD8A, CD3Z and CXCL9 gene expression: cluster A=inflamed high, cluster B=inflamed low, cluster C=uninflamed. distribution of intrinsic subtypes and TILs (%) are depicted above in h-bar plots.
Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany. The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15. PMID: 30988029.
Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B. Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2. PMID: 30831560; PMCID: PMC6403442.
Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C; BRIDGE Consortium e.V.. Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder. Virchows Arch. 2019 Feb;474(2):209-217. doi: 10.1007/s00428-018-2496-9. Epub 2018 Nov 27. PMID: 30483954.
Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5. PMID: 30528808.
(A) Representative images of tumour cell (TC) membrane staining of all four applied assays.
Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P. Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy. Urol Oncol. 2018 Dec;36(12):530.e19-530.e27. doi: 10.1016/j.urolonc.2018.09.003. Epub 2018 Nov 13. Erratum in: Urol Oncol. 2019 Mar;37(3):227. doi: 10.1016/j.urolonc.2018.12.019. PMID: 30446441.
Eckstein M, Sikic D, Strissel PL, Erlmeier F; BRIDGE Consortium Germany. Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer. Eur Urol. 2018 Oct;74(4):527-529. doi: 10.1016/j.eururo.2018.06.028. Epub 2018 Jul 12. PMID: 30007816.
Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P. mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. Int J Mol Sci. 2018 Oct 30;19(11):3396. doi: 10.3390/ijms19113396. PMID: 30380731; PMCID: PMC6274690.
Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x. PMID: 30258198; PMCID: PMC6158275.
Stratification of the test cohort (n = 80) for CDKN2A expression identified a subgroup of 8/80 (10.0%) patients with the highest CDKN2A expression who had a much worse RFS (a) and DSS (b) compared to the rest of the cohort.
Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2. PMID: 29525349.
Otto W, van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A. Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer. Int J Urol. 2018 May;25(5):442-449. doi: 10.1111/iju.13532. Epub 2018 Feb 22. PMID: 29473226.
Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P. Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer. Transl Oncol. 2018 Apr;11(2):467-476. doi: 10.1016/j.tranon.2018.02.001. Epub 2018 Feb 23. PMID: 29477637; PMCID: PMC5834659.
Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol Immunother. 2018 Mar;67(3):403-412. doi: 10.1007/s00262-017-2093-9. Epub 2017 Nov 17. PMID: 29150702; PMCID: PMC11028240.
Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P. A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. PMID: 29599921; PMCID: PMC5871092.
Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P. FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. Oncotarget. 2017 Jul 18;8(29):47595-47606. doi: 10.18632/oncotarget.17394. PMID: 28498805; PMCID: PMC5564590.
Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A. Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget. 2017 Jun 28;8(40):67684-67695. doi: 10.18632/oncotarget.18804. PMID: 28978063; PMCID: PMC5620203.
Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J; Bridge Consortium. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis. PLoS One. 2017 Jun 20;12(6):e0179602. doi: 10.1371/journal.pone.0179602. PMID: 28632777; PMCID: PMC5478149.
Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W. High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. Transl Oncol. 2017 Jun;10(3):340-345. doi: 10.1016/j.tranon.2017.01.013. Epub 2017 Mar 22. PMID: 28342317; PMCID: PMC5367846.
Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10. PMID: 28074276.
Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium. ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. Urol Int. 2017;98(3):282-289. doi: 10.1159/000453670. Epub 2016 Dec 17. PMID: 27992871.
Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W. ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). Virchows Arch. 2016 Nov;469(5):547-552. doi: 10.1007/s00428-016-2002-1. Epub 2016 Aug 11. PMID: 27514658.
Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P. Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer. Anticancer Res. 2016 Oct;36(10):5205-5213. doi: 10.21873/anticanres.11091. PMID: 27798881.
Molekulare Klassifikation des Harnblasenkarzinoms – Mögliche Ähnlichkeit zum Mammakarzinom
Wirtz, R.M., Fritz, V., Stöhr, R. et al. Molekulare Klassifikation des Harnblasenkarzinoms.Pathologe 37, 52–60 (2016). https://doi.org/10.1007/s00292-015-0134-8